Atazanavir (Reyataz)

Selected Posters and Abstracts
Atazanavir (Reyataz)

•	Once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATV/r) with tenofovir (TDF)/emtricitabine (FTC) in antiretroviral naive HIV-1 infected patients: 24-week results from COL103952 (ALERT). Smith and others.
•	The safety and the effectiveness of antiretroviral therapy containing atazanavir/ritonavir (ATV/r) with or without tenofovir (TDF). A Guelar and others.
•	Acetaminophen pharmacokinetics and hepatic transaminases are unaffected on atazanavir/ritonavir coadministration. T Eley sand others.
•	Improvement of lipidic metabolism does not change the cardiovascular risk score in 13 months of observation of patients switched to atazanavir-based regimen. M Colafigli and others.
•	Induction/maintenance strategy with atazanavir/ritonavir. D J Ward and others.
•	Lipids and lipoproteins in HIV-subjects treated with lopinavir/ritonavir (L) or atazanavir/ritonavir (A) based antiretroviral therapy. A Trein and others.
•	Effect of atazanavir (ATV) versus other protease inhibitor (PI)-containing antiretroviral combination therapy on endothelial function in HIV-infected persons: randomized controlled trial. A Flammer and others.
•	Atazanavir has a better impact on lipid profiles than fosamprenavir and lopinavir in patients matched for baseline triglycerides and cholesterol. S De Wit and others.
•	A 100% atazanavir urolitzhiasis. J-YLiotier and others. <— Conference Main Page

FDA-Approved
HIV and AIDS Treatments